SELECTED ARTICLES

1. Kolomeyer A, Kim HJ, Khouri A, Zarbin MA, Fechtner RD, Lama PJ, Bhagat N. 23-gauge pars plana viterctomy with Baerveldt tube insertion. Eur J Ophthalmol. In press.

2. Berezina TL, Khouri AS, Kolomeyer AM, Clancy PS, Fechtner RD. Peripheral visual field thresholds using Humphrey Field Analyzer program 60-4 in normal eyes. Eur J Ophthalmol 2011;21(4)415-21.

3. Fechtner RD, Harasymowycz P, Nixon DR, Vold SD, Zaman F, Williams JM, Hollander DA. Twelve-week, randomized, multicenter study comparing a fixed combination of brimonidine-timolol with timolol as therapy adjunctive to latanaprost. Clin Ophthalmol 2011;5:945-53.

4. Fechtner RD, Godfrey DG, Budnez D, Stewart WC, Jasek MC. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea 2010;29(6):618-21.

5. Roth DB, Verma V, Realini T, Prenner JL. Feuer WJ, Fechtner RD. Long-term incidence and timing of intraocular hypertension after intravitreal of trimcinolone acetonide injection. Ophthalmology 2009;116(3):455-60.

6. Roth DB, Realini T, Feuer WJ, Radhakrishnan R, Gloth J, Heimmel MR, Fechtner RD, Yarian DL, Green SN. Short-term complications of intravitreal injection of trimcinolone acetonide. Ophthalmology 2008;28(1):66-70.

7. Khouri AS, Szirth BC, Fechtner, RD. Software assisted optic nerve assessment for glaucoma tele-screening. Telemed J E Health 2008; Apr 14(3):261-5.

8. Dueker DK, Singh K, Lin SC, Fechtner RD, Minckler DS, Samples JR, Schuman JS. Corneal thickness measurement in the management of primary open-angle glaucoma. Ophthalmology 2007;114(9):1779-87.

9. Lin SC, Singh K, Jampel HD, Hodapp EA, Smith SD, Francis BA, Dueker DK, Fechtner RD, et al. Optic nerve head and retinal nerve fiber layer analysis: a report by the American Academy of Ophthalmology. Ophthalmology 2007;114(10):1937-49.

10. Khouri AS, Szirth BC, Fechtner, RD, et al. DICOM transmission of simultaneous stereoscopic images of the optic nerve in patients with glaucoma. J Telemed Telecare 2007;13(7):337-40.

11. Khouri AS, Realini T, Fechtner RD. Use of fixed-dose combination drugs for the treatment of glaucoma. Drugs Aging 2007;24(12);1007-16.

12. Dueker DK, Singh K, Fechtner, RD. Corneal thickness measurement in the management of primary open-angle glaucoma: a report by the American Academy of Ophthalmology. Ophthalmology 2007;114(9):1779-87.

13. Bhagat N, Nissirios N, Potdevin L, Chung J, Lama P, Zarbin M, Fechtner R, Guo S, Chu D, Langer P. Complications in resident-performed phacoemulsification cataract surgery at New Jersey Medical School. Br J Ophthalmol 2007; 91(10):1315-7.

14. Fechtner RD, Khouri AS. Evolving global risk assessment of ocular hypertension to glaucoma. Curr Opin Ophthalmol 2007;18(2):104-9.

15. Khouri A, Szirth B, Bhagat N, Fechtner R. Comment on screening and diabetes mellitus. Ophthalmology 2007;
114(2):398-400.

16. Turbin RE, Ahukanna I, Szirth BC, Grant G, Bennett HL, Fechtner RD. Intra-ocular pressure during lumbar disc surgery. Anaesthesia 2007; 62(1):91; [author reply]: 92.

17. Mansberger SL, Hughes BA, Gordon MO, Spaner SD, Beiser JA, Cioffi GA, Kass MA; Ocular Hypertension Treatment Study Group. Comparison of initial intraocular pressure response with topical beta-adrenergic antagonists and prostaglandin analogues in African American and white individuals in the Ocular Hypertension Treatment Study. Arch Ophthalmol 2007;125(4):454-9.

18. Khouri AS, Szirth BC, Realini T, Fechtner RD. Comparison of digital and film stereo photography of the optic nerve in evaluation of patients with glaucoma. Telemed J E Health 2006;12(6):632-8.

19. Fechtner RD, et. al. Short-term treatment of cocaine and/or methamphetamine abuse with vigabatrin: ocular safety pilot results. Arch Ophthalmol 2006;124(9):1257-62.

20. Fechtner R. Glaucoma following intravitreal steroid therapy for age-related macular degeneration. Ophthalmol Times 2006 Mar;(x Suppl):10-11.

21. Khouri AS, Forofonova TI, Fechtner RD. Laser suture lysis through thick blebs using the Blumenthal lens. Arch Ophthalmol 2006;124(4):544.

22. Kymes SM, Kass MA, Anderson DR , Miller JP, Gordon MO for the Ocular Hypertension Treatment Study Group (OHTS). Management of ocular hypertension: a cost-effectiveness approach from the Ocular Hypertension Treatment Study. Am J Ophthalmol 2006;141(6):997-1008.

23. Khouri AS, Newman FR, Fechtner RD. Ultrasound biomicroscopy demonstrating etiology of a spontaneous filtering bleb. Eye [Internet]. 2006 [2006 Feb. 24].

24. Levine RA, Demirel S, Fan J, Keltner JL, Johnson CA, Kass MA; Ocular Hypertension Treatment Study Group. Asymmetries and visual field summaries as predictors of glaucoma in the ocular hypertension treatment study. Invest Ophthalmol Vis Sci 2006;7(9):3896-903.

25. Kymes SM, Kass MA, Anderson DR, Miller JP, Gordon MO; Ocular Hypertension Treatment Study Group (OHTS). Management of ocular hypertension: a cost-effectiveness approach from the Ocular Hypertension Treatment Study. Am J Ophthalmol 2006;141(6):997-1008.

26. Fechtner R, McCarroll K, Lines C, Adamsons I. Efficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: combined analysis of pooled data from two large randomized observer and patient-masked studies. J Ocul Pharmacol Ther 2005;21(2):242-9.

27. Parrish RK, Schiffman JC, Feuer WJ, et al; Ocular Hypertension Treatment Study (OHTS) Group. Test-retest reproducibility of optic disk deterioration detected from stereophotographs by masked graders. Am J Ophthalmol 2005; 140(4):762-4.

28. Khouri A, Szirth B, Fechtner RD. Detecting age-related macular degeneration: technologies are best compared when standardized [letter]. Arch Ophthalmol 2005;123(8):1157.

29. Friedman DS, Wilson MR, Liebmann JM, Fechtner RD, Weinreb RN. An evidence-based assessment of risk factors for the progression of ocular hypertension and glaucoma. Am J Ophthalmol 2004;138(3 Suppl):19-31.

20. Weinreb R, Friedman D, Fechtner R, et al. Risk assessment in the management of patients with ocular hypertension.
Am J Ophthalmol 2004;138(3):458-67.

31. Realini T, Fechtner RD, Atreides SP, Gollance S. The uniocular drug trial and second-eye response to glaucoma medications. Ophthalmology 2004;111:421-6.

32. Fechtner RD, Airaksinen PJ, Getson AJ, Lines CR, Adamsons IA, et al. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmol Scand 2004;82(2):42-8.

33. Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol 2004;15:132-5.

34. Higginbotham E, M Gordon, et al. for The Ocular Hypertension Treatment Study: topical medication delays or prevents primary open-angle glaucoma in African American individuals. Arch Ophthalmol 2004;122: 813-20.

35. Brandt J, Beiser J, Gordon M, Kass M; Ocular Hypertension Treatment Study (OHTS) Group. Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study. Am J Ophthalmol 2004;138:717-22.

36. Coleman AL, Gordon MO, Beiser JA, Kass MA. Ocular Hypertension Treatment Study (OHTS) Group. Baseline risk factors for the development of POAG in the Occular Hypertension Treatment Study. Am J Ophthalmol 2004;138(4):684-5.

37. Higginbotham E, Gordon M, et al; Ocular Hypertension Treatment Study Group. Topical medication delays or prevents primary open-angle glaucoma in African American individuals. Arch Ophthalmol 2004;122:813-20.

38. Zangwill LM, Weinrab RN, Berry CC, Smith AR, Dirkes KA, Liebmann JM, Brandt JD, Trick G, Cioffi GA, Coleman AL, Piltz-Seymour JR, Gordon MO, Kaas MA for the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. The Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study: Study Design and baseline Factors. Am J Ophthalmol 2004;137:219-27.

39. Zangwill LM, Weinrab RN, Berry CC, Smith AR, Dirkes KA, Coleman AL, Piltz-Seymour JR, Liebmann JM, Cioffi GA, Trick G, Brandty JD, Gordon MO, Kaas MA for the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. Arch Ophthalmol 2004;122:22-8.

40. Whitson JT, Henry C, Hughes B, Lee DA, Terry S, Fechtner RD. Comparison of the safety and efficacy of dorzolamide 2% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. J Glaucoma 2004;13:168-73.

41. Alvarez TL, Gollance SA, Thomas GA, et al. The Proview phosphene tonometer fails to measure ocular pressure accurately in clinical practice. Ophthalmology 2004;111:1077-85.

42. Lama PJ, Fechtner RD. Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol 2003;48:314-46.

43. Keltner J, Johnson C, et al. Classification of visual field abnormalities in the ocular hypertension treatment study.
Arch Ophthalmol 2003;121: 643-50.

44. Kass MA, Heuer DK, Higginbotham EJ, et al. for The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13.

45. Gordon MO, Beiser JA, Brandt JD, et al. for The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:714-20.

46. Realini T, Fechtner RD. 56,000 ways to treat glaucoma. Ophthalmology 2002;109(11):1955-6.

47. Delgado MF, Nguyen NT, Cox TA, Singh K, Lee DA, Dueker DK, Fechtner RD, Juzych MS, Lin SC, Netland PA, Pastor SA, Schuman JS, Samples JR. Automated perimetry: a report by the American Academy of Ophthalmology. Ophthalmology 2002;109:2362-74.

48. Fechtner RD, Singh K. Maximal glaucoma therapy (review). J Glaucoma 2001;10:S73-S75.

49. Lama PJ, Pagan-Duran B, Eagle RC, Fechtner RD. Toxicity of subconjunctival injection of mitomycin C. Invest Ophthalmol Vis Sci 2001;42(4 Suppl):S545.

50. Essock EA, Sinai MJ, Bryant RD, Fechtner RD, Chen PP, Mills RP. Detection of glaucoma by Fourier analysis of polarimetry data using discriminant analysis. Invest Ophthalmol Vis Sci 2001;42(4 Suppl):S17.

51. Fechtner RD. Combination drug therapy helps patient compliance. Ophthalmology Times 2001 March;26.

52. Fechtner RD. Better compliance possible with combo glaucoma product. Ophthalmology Times 2001 March;25.

53. Fechtner RD. Timolol hemihydrate effective as maleate. Ophthalmology Times 2001 March;22.

54. Fechtner RD. Image analysis: is it ready for clinical practice? Ocular Surgery News 2001 Feb 15;28-9.

55. Fechtner RD. New class of medications of lowering IOP addressed. Ophthalmology Times 2001 Feb;8 -10.

56. Higginbotham EJ, Ball SF, Berlin MJ, Fechtner RD. Developing therapy decisions for the glaucoma patient. EyeWorld 2001 Jan;32.

57. Piltz J, Gross R, Shin D, et al. Contralateral effect of topical beta-adrenergic antagonists in initial one-eyed trials in the ocular hypertension treatment study. Am J Ophthalmol 2000;130:441-53.

58. Essock EA, Sinai MJ, Fechtner RD, Srinivasan N, Bryant FD. Fourier analysis of nerve fiber layer measurements from scanning laser polarimetry in glaucoma: emphasizing shape characteristics of the 'double-hump' pattern. J Glaucoma 2000;9:444-52.

59. Realini TA, Fechtner RD. Target intraocular pressure in glaucoma management. Glaucoma diagnosis and management 2000;13(3):1-19.

60. Khouri AS, Deebs LS, Tamburro CH, Fechtner RD, Zimmerman TJ. Isolated cotton-wool spot in a patient with hepatitis C. Ann Ophthalmol 2000;32:183 -5.

61. Budo CJ, Baikoff GD, Fechtner RD, Zaldivar R. Cohesive viscoelastics may be useful for phakic IOLs. Ocular Surgery News 2000;18(17):27.

62. Realini T, Fechtner RD. Target intraocular pressure in glaucoma management. Glaucoma diagnosis and management
2000 Sept;407-15.

63. Fechtner RD. Cohesive viscoelastics may be useful for phakic IOLs. Ocular Surgery News 2000 Sept;27-8.

64. Fechtner RD, Lama PJ. The future of glaucoma diagnosis and therapy. Primary care of the glaucomas 2000;
419-25.

65. Fechtner RD. Initial medical management of open-angle glaucoma. J Glaucoma 2000;9:83-6.

66. Sinai MJ, Essock EA, Fechtner RD, Srinivasan N. Diffuse and localized nerve fiber layer loss measured with a scanning laser polarimeter: sensitivity and specificity of detecting glaucoma. J Glaucoma 2000;9:154-62.

67. Bryant FD, Sinai RD, Fechtner RD, Essock EA. An extension of Fourier analysis techniques of nerve fiber layer measurements from scanning laser polarimetry. Invest Ophthalmol Vis Sci 2000;41(4 Suppl):S92.

68. Fechtner RD, Lama PJ. A community based evaluation of efficacy and tolerability of Brimonidine as mono, replacement or combination therapy in African Americans with open angle glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 2000;41 Suppl:281.

BOOKS, MONOGRAPHS AND CHAPTERS

1. Fechtner RD, Khouri AS. Early vision loss after trabeculectomy. In: Feldman R, editor. Operative Compliactions in Glaucoma: Complications of Galucoma Surgery. New York, NY: Oxford University Press. In press.

2. Fechtner RD, Asbell PA, Kahook MY. Ocular surface disease in the presence of glaucoma [CME-certified monograph]. Glaucoma Today and Advanced Ocular Care. February/March 2011.

3. Weinreb RN, Fechtner RD, Coleman AL, et al. Treatment of risk in the glaucoma continuum: CME-certified monograph. 2006.

4. Weinreb RN, Fechtner RD , Friedman DS, Liebmann JM, Singh K. Treatment of risk in the glaucoma continuum: CME certified CD-Rom [CD ROM]. 2006.

5. Fechtner RD, Hitchings R. Indications for glaucoma surgery. In: Weinreb RN, Crowston JC, editors. Glaucoma surgery: open angle glaucoma. The Hague, The Netherlands: Kugler; 2005. p 9-20.

6. Fechtner RD, Realini T. What is maximal tolerated medical thearpy? In: Susanna Jr R, Weinreb RN, editors. Glaucoma: answers in glaucoma. Rio de Janeiro, Brazil: Cultura Medica; 2005. p. 95-98.

7. Fechtner RD, Liebmann JM, Singh K. Glaucoma 2005: Mastering tools and techniques for the 21st century. Ophthalmology Times 2005;30(CME supplement 18).

8. Realini T, Fechtner RD. Glaucoma. In: Rakel RE, Bope ET, editors. Conn's current therapy 2003. Philadelphia: WB Saunders; 2003. p 187-190.

9. Fechtner RD, Realini TR. How I treat glaucoma. In: Rakel RE, Bope ET, editors. Conn’s current therapy. Philadelphia: WB Saunders; 2002.

10. Realini T, Fechtner RD. Glaucoma. In: Rakel RD, Bope ET, editors. Conn's current therapy 2002. Philadelphia: WB Saunders; 2002. p 945-948.

11. Fechtner RD, Lama PJ. The future of glaucoma diagnosis and therapy. In: Fingeret M, Lewis TL, editors. Primary care of the glaucomas. 2nd ed. New York: McGraw-Hill; 2001. p 419-26.

12. Fechtner RD. Beta blockers. In: Netland PA, Allen RC, editors. Glaucoma medical therapy: principles and management. San Francisco: American Academy of Ophthalmology. Forthcoming.

13. Realini AR, Khouri AS, Fechtner RD. Key therapeutic signs: retina and vitreous. In: Gross RL, editor. Clinical glaucoma management: critical signs in diagnosis and management. Philadelphia: W B Saunders; 2000. p :383-400.

14. Fechtner RD,editor. New surgical procedures for glaucoma II. Mediguide to Ophthalmology. 1999;9(1):1-8.

15. Fechtner RD,editor. Giant cell (temporal) arteritis. Mediguide to Ophthalmology. 1999;9(4):1-6.

16. Fechtner RD. Beta blockers. In: Allen RC, Netland PA, editors. Glaucoma medical therapy: principles and management. San Francisc : The Foundation of the American Academy of Ophthalmology; 1999. p 25-46.

17. Zimmerman TJ, Kooner K, Sharir M, Fechtner RD. Textbook of ocular pharmacology. Philadelphia: Lippincott-Raven; 1997.

18. Fechtner RD, Kooner KS. Definitions and classification of glaucoma. In: Zimmerman TJ, Kooner K, Sharir M, Fechtner RD, editors. Textbook of ocular pharmacology. Philadelphia: Lippincott-Raven; 1997.

19. Fechtner RD, Karunaratne N, Nardin G, Zimmerman TJ. Surgery for glaucoma and related conditions. In: Jaffe N, editor. Atlas of ophthalmic surgery. 2nd ed. Philadelphia: J B Lippincott; 1996. p 159-82.

20. Fechtner RD, Ikram F, Essock EA. Advances in quantitative optic nerve analysis. In: Burde RM, Slamovits TL, editors. Volume 3, Advances in clinical ophthalmology. St. Louis: Mosby Year Book; 1996. p 203-24.

21. Fechtner RD, Dreher AW, Weinreb RN. The laser scanning ophthalmoscope. In: Varma R, Spaeth G, Parker K, editors. The Optic disc in glaucoma. Philadelphia: J B Lippincott; 1993. p 269-76.

22. Fechtner RD, Weinreb RN. Examining and recording the appearance of the optic nerve head. In: Starita RJ, editor. Volume 12, Clinical signs in ophthalmology. St. Louis: Mosby Year Book; 1991. p 2-15.

23. Starita RJ, Fechtner RD, Fellman RN. Ocular and systemic side effects of topical epinephrine and dipivefrin. In: Spaeth GL, Sherwood MB, editors. Complications of glaucoma therapy. Thorofare, NJ: SLACK; 1990:19-32.

REVIEWS

1. Khouri A, Fechtner RD. Glaucoma Surgery [review]. J Glaucoma 2005;14(4):328.

2. Fechtner RD. Target IOP for advanced glaucoma. Glaucoma Today 2004 Jan;1-3.

3. Fechtner RD, Lama PJ. Clinical pathways in glaucoma [review]. J Glaucoma 2002; 11:75.

4. Fechtner RD, Lama PJ, Walton W. Atlas of cataract surgery [review]. J Glaucoma 2001;10:501-3.

5. Realini T, Fechtner RD. Target intraocular pressure in glaucoma management. Ophthalmol Clin North Am 2000;13:1-9.

6. Fechtner RD, Lama P. How to improve your trabeculectomy technique [review]. Rev Ophthalmol 1999;VI:70-9

7. Fechtner RD, Lama P. Advances in optic nerve head analysis in glaucoma. Semin Ophthalmol 1999;14:180-188.

8. Realini TA, Fechtner RD. Glaucoma management - what we know about the new medications [review].
Rev Ophthalmol 1998:59-67.

9. Fechtner RD. Source book of ophthalmology [book review]. J Glauocma 1996;5:436.

10. Fechtner RD. Bookends pro [software review]. J Glaucoma 1995;4:300-1.

REPORTS

1. Fechtner RD. New era for medical treatment of glaucoma: prostaglandin analogues have replaced beta blockers as first-line medical therapy for glaucoma. Ophthalmol World Rep [in Chinese]. December 2010(suppl).

2. Fechtner RD. The "how" and the "whom" of the EX-PRESS device. Glaucoma Today. Early Spring 2011.

3. Fechtner RD. Reducing the preservative load in glaucoma therapy. Adv Ocular Care. May/June 2011.